{"id":6303,"date":"2024-11-29T17:03:00","date_gmt":"2024-11-29T11:33:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6303"},"modified":"2024-12-02T18:28:24","modified_gmt":"2024-12-02T12:58:24","slug":"non-small-cell-lung-cancer-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market","title":{"rendered":"Non-Small Cell Lung Cancer Market: Treatments and Market Forecast"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a33c978750ed\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a33c978750ed\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#How_Common_is_Lung_cancer\" >How Common is Lung cancer?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Non-Small_Cell_Lung_Cancer_Therapeutics_landscape\" >Non-Small Cell Lung Cancer Therapeutics landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Breakthroughs_in_NSCLC_Advancing_Targeted_Therapies_and_Precision_Medicine\" >Breakthroughs in NSCLC: Advancing Targeted Therapies and Precision Medicine<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Key_Advancements_in_EGFR-Non_Small_Cell_Lung_Cancer_Treatment\" >Key Advancements in EGFR-Non Small Cell Lung Cancer Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Companies_investing_in_advancing_Non-small_cell_lung_cancer_Market\" >Companies investing in advancing Non-small cell lung cancer Market<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Advancing_Treatments_for_Rare_Biomarkers_in_Non-Small_Cell_Lung_Cancer\" >Advancing Treatments for Rare Biomarkers in Non-Small Cell Lung Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Non-small_cell_lung_cancer_Pipeline\" >Non-small cell lung cancer Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Advancing_NSCLC_Care_Tackling_the_Global_Healthcare_Burden_Through_Precision_Medicine_and_Early_Detection\" >Advancing NSCLC Care: Tackling the Global Healthcare Burden Through Precision Medicine and Early Detection<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\/#Non-small_cell_lung_cancer_Market_forecast\" >Non-small cell lung cancer Market forecast<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>According to the World Health Organization (WHO), in 2022, there were approximately <strong>2.5 million new cases of lung cancer globally<\/strong>, which accounted for <strong>12.4% of all newly diagnosed cancer cases<\/strong>. Lung cancer continues to be one of the most common and deadly malignancies worldwide, with significant contributions to global cancer morbidity and mortality rates.<strong> <\/strong><\/p>\n\n\n\n<p>The global burden of cancer is projected to increase significantly, with more than <strong>35 million new cases anticipated by 2050<\/strong>. Lung cancer remains the most common cancer worldwide, being the <strong>leading cancer in men<\/strong> and the <strong>second most common in women<\/strong>. Recent estimates indicate that approximately <strong>53.5 million people<\/strong> were alive within five years of being diagnosed with cancer. Globally, about <strong>1 in 5 individuals<\/strong> develop cancer during their lifetime, with <strong>1 in 9 men<\/strong> and <strong>1 in 12 women<\/strong> succumbing to the disease. <\/p>\n\n\n\n<p>According to the <strong>Global Cancer Observatory<\/strong> (IARC), ten types of cancer accounted for around <strong>two-thirds of new cases and deaths globally<\/strong> in 2022, covering data from <strong>185 countries<\/strong> across <strong>36 cancer types<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-common-is-lung-cancer\"><span class=\"ez-toc-section\" id=\"How_Common_is_Lung_cancer\"><\/span>How Common is Lung cancer?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to<strong> Cancer.org, <\/strong>Lung cancer (both small cell and non-small cell) is the most commonly diagnosed and second most common cancer in both men and women. About <strong>13%<\/strong> of all new cancers are <strong>lung cancers.<\/strong><\/p>\n\n\n\n<p>Around <strong>80-85% <\/strong>of all cancers are <strong>Non-small cell lung cancer (NSCLC). <\/strong>The main subtypes of the NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.<\/p>\n\n\n\n<p>The age-adjusted Non-small cell lung cancer incidence is <strong>47.2 per 100,000<\/strong> individuals and is most frequently diagnosed among people between <strong>65 and 74 years old <\/strong>(SEER), in the US.<\/p>\n\n\n\n<p>According to the American Cancer Society estimates, the incidence of NSCLC in the United States in <strong>2018 <\/strong>was about<strong> 234,030 new cases,<\/strong> of which <strong>121,680 were men<\/strong> and <strong>112,350 were women.<\/strong><\/p>\n\n\n\n<p>According to the WHO, if we talk about the incidence of the subtypes of NSCLC, <strong>squamous cell carcinoma<\/strong> accounts for <strong>25\u201330% of cases<\/strong> of lung cancers, <strong>adenocarcinoma <\/strong>accounts for <strong>40% of cases<\/strong> whereas large cell carcinoma accounts for <strong>10\u201315%.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"561\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png\" alt=\"Non-Small Cell Lung Cancer Market Key Insights\" class=\"wp-image-30472\" style=\"width:840px;height:auto\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-300x164.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-150x82.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-768x421.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1536x841.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-2048x1122.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Non-Small_Cell_Lung_Cancer_Therapeutics_landscape\"><\/span>Non-Small Cell Lung Cancer Therapeutics landscape<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\">Non-Small Cell Lung Cancer Treatment trends<\/a> have shifted from molecular histologic subtype-based towards targeted therapies. The current treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, immune checkpoint inhibitors, or some combination of these, depending on the type of cancer, stage of the disease, and overall health as well as the age of the patient.<\/p>\n\n\n\n<p>Early diagnosis of the cancer is necessary as most <strong>stage I\/II NSCL<\/strong>C can be surgically removed. Earlier, the NSCLC therapy market revolved around chemotherapy regimens.<\/p>\n\n\n\n<p>The therapeutic efficacy of Non-small cell lung cancer (NSCLC) has significantly improved with the introduction of targeted therapies. In case of mutations, targeted therapies are the best option.<\/p>\n\n\n\n<p>The targeted therapies include anti-angiogenesis therapy,<strong> epidermal growth factor receptor (EGFR) inhibitors, ALK inhibitors, an immune checkpoint inhibitor<\/strong>, and drugs that target other genetic changes.<\/p>\n\n\n\n<p>Moreover, the cancerous cells are tested for <strong>epidermal growth factor receptor (EGFR),<\/strong> which, in excess, facilitates the faster growth of the cells. Drugs like<strong> Afatinib (Gilotrif), Gefitinib (Iressa), Erlotinib (Tarceva), Osimertinib (Tagrisso), Dacomitinib (Vizimpro), etc.<\/strong> block the EGFR signalling pathway helping in treating cancer.<\/p>\n\n\n\n<p>Another cause of Non-small cell lung cancer is a rearrangement in a gene called <strong>ALK (Anaplastic lymphoma kinase). Drugs such as Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena),<\/strong> and others target the mutated ALK protein, hampering cell division in excess.<\/p>\n\n\n\n<p>If the mutation in the <strong>BRAF gene<\/strong> causes NSCLC, drugs such as <strong>Dabrafenib (Tafinlar) and Trametinib (Mekinist) <\/strong>are used to<strong> treat metastatic NSCLC.<\/strong><\/p>\n\n\n\n<p>Programmed cell death to beat cancer has brought a revolutionary transformation in the cancer treatment landscape. Immune checkpoint inhibitors, fundamentally those that act by blocking the programmed cell death receptor-1 (PD-1) and its ligand the programmed cell death ligand-1 (PD-L1), have emerged as novel NSCLC treatment option, demonstrating undoubted superiority over chemotherapy in terms of efficacy.\u00a0 <strong>Several regulatory organizations globally have recognized immunotherapy as one of the viable options for <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-epidemiology-forecast\">Non-small cell lung cancer treatment.<\/a><\/strong> The available approved immune checkpoint modulators such as Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Atezolizumab (Tecentriq) are recommended in first-line and second-line metastatic NSCLC.<\/p>\n\n\n\n<p><strong>IMFINZI (durvalumab)<\/strong> is <strong>approved <\/strong>for unresectable<strong> Stage III NSCLC<\/strong> and as maintenance after chemoradiotherapy in locally advanced disease.<\/p>\n\n\n\n<p><strong><em>To explore the full list of approved drugs in the NSCLC treatment market, <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-outlook\"><strong><em>click here.<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Breakthroughs_in_NSCLC_Advancing_Targeted_Therapies_and_Precision_Medicine\"><\/span>Breakthroughs in NSCLC: Advancing Targeted Therapies and Precision Medicine<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/recent-developments-in-nsclc-treatment\">Recent advancements in non-small cell lung cancer (NSCLC) treatment<\/a> emphasize significant progress in targeted therapies, immunotherapy, and precision medicine. Highlights from 2024 include breakthroughs in clinical trials such as <strong>osimertinib (LAURA study),<\/strong> demonstrating remarkable progression-free survival in <strong>EGFR-mutant NSCLC, and lorlatinib (CROWN trial), <\/strong>showing superior efficacy for ALK-positive cases, particularly in managing brain metastases. Novel approaches like <strong>datopotamab deruxtecan, ivonescimab, and tumor-targeting fields (TTFields) therapy<\/strong> gained momentum with promising clinical results and regulatory approvals. Emerging therapies targeting biomarkers such as <strong>PD-L1, EGFR, and KRAS<\/strong> have reshaped treatment paradigms, while advances in artificial intelligence and big data analytics promise enhanced diagnostics and personalized care. With a robust pipeline of innovative treatments and collaborations, the NSCLC treatment landscape is poised for significant growth and improved patient outcomes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Advancements_in_EGFR-Non_Small_Cell_Lung_Cancer_Treatment\"><\/span><strong>Key Advancements in EGFR-Non Small Cell Lung Cancer Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>EGFR-Non-Small Cell Lung Cancer mutations are one of the most common genetic alterations. These mutations are critical in determining treatment approaches, as EGFR tyrosine kinase inhibitors (TKIs) have been a standard therapy. However, resistance to these treatments, particularly from mutations like T790M and exon 20 insertions, poses significant challenges. Emerging therapies, including third-generation TKIs, antibody-drug conjugates, and novel agents like<strong> Telisotuzumab Vedotin,<\/strong> are showing promise in overcoming resistance mechanisms. Companies like <strong>AstraZeneca, AbbVie, and Dizal Pharmaceuticals<\/strong> are at the forefront of this therapeutic evolution, aiming to address unmet needs and improve survival rates for EGFR-mutant NSCLC patients.<\/p>\n\n\n\n<p><strong><em>For a deeper dive into the EGFR-Non Small Cell Lung Cancer Treatment Market, <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/egfr-nsclc-treatment-market-outlook\"><strong><em>click on our latest blog<\/em><\/strong><\/a><strong><em> curated specifically for this topic!<\/em><\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Companies_investing_in_advancing_Non-small_cell_lung_cancer_Market\"><\/span>Companies investing in advancing Non-small cell lung cancer Market<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Key pharma companies involved in propelling the Non-small cell lung cancer therapy market and trying to dominate the significant major NSCLC market share are:<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"284\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-1024x284.png\" alt=\"\" class=\"wp-image-30480\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-1024x284.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-300x83.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-150x42.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-768x213.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-1536x427.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/01192633\/Key-Players-Working-in-the-Non-Small-Cell-Lung-Cancer-Treatment-Market-2048x569.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Advancing_Treatments_for_Rare_Biomarkers_in_Non-Small_Cell_Lung_Cancer\"><\/span>Advancing Treatments for Rare Biomarkers in Non-Small Cell Lung Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The evolving landscape of rare biomarkers in NSCLC, including <strong>METex14 skipping alterations, ALK rearrangements, and HER-2 mutations,<\/strong> has ushered in transformative advancements in diagnostics and therapies. FDA-approved drugs like <strong>TEPMETKO (Tepotinib) and Capmatinib (Tabrecta)<\/strong> now provide targeted treatments for METex14 skipping, significantly improving response rates and survival outcomes in previously under-served patient populations. Emerging therapies such as <strong>APL-101 and vebreltinib<\/strong> further promise innovative options, addressing treatment resistance and enhancing clinical efficacy. Despite challenges in cost-effectiveness, these advancements highlight the critical role of personalized medicine in offering better quality of life and survival outcomes for patients with rare genetic alterations in NSCLC.<\/p>\n\n\n\n<p><strong>To learn more about the advancements in rare biomarkers for NSCLC and how they are transforming treatment options, check out our latest blog prepared exclusively on this topic. <\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/biomarkers-in-non-small-cell-lung-cancer-therapy-market\"><strong>Click here!<\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Non-small_cell_lung_cancer_Pipeline\"><\/span>Non-small cell lung cancer Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current research is looking toward the employment of effective therapies, such as targeted therapies, personalized therapies, and Immunotherapy. Targets currently being used or investigated in the treatment of NSCLC include the human epidermal growth factor (HER) family of receptors, <strong>EGFR, KRAS, ALK, PI3K\/AKT\/mTOR, IGF-1R, MET, ROS, Monoclonal antibodies, T-cell therapies, immune checkpoint inhibitors, <\/strong>etc.<\/p>\n\n\n\n<p>Drugs, such as <strong>Zipalertinib, YK-029A, TAS3351, NVL-330, JS-113, JANX-008, IN-119873,<\/strong> and others are being developed as the highly effective Non-small cell lung cancer therapies.<\/p>\n\n\n\n<p>The launch of these emerging NSCLC therapies is expected to significantly impact <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-pipeline-insight\">Non-small Cell Lung Cancer treatment scenario <\/a>in the coming years, 2020-2034.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Advancing_NSCLC_Care_Tackling_the_Global_Healthcare_Burden_Through_Precision_Medicine_and_Early_Detection\"><\/span>Advancing NSCLC Care: Tackling the Global Healthcare Burden Through Precision Medicine and Early Detection<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>NSCLC remains a significant global health burden due to its late-stage diagnoses, high treatment costs, and limited access to advanced therapies in many regions. <\/p>\n\n\n\n<p>Despite substantial advancements in targeted therapies and immunotherapies, disparities in care and affordability hinder widespread benefits. Addressing this burden requires a multifaceted approach, including the expansion of healthcare infrastructure, greater awareness campaigns, and a stronger emphasis on early detection through improved screening programs. <\/p>\n\n\n\n<p>Personalized medicine and the development of cost-effective treatment options are pivotal in reducing mortality rates and enhancing the quality of life for NSCLC patients worldwide.<\/p>\n\n\n\n<p><strong><em>To learn more about how innovative therapies are reshaping the fight against the global burden of NSCLC, <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\"><strong><em>click here.<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Non-small_cell_lung_cancer_Market_forecast\"><\/span>Non-small cell lung cancer Market forecast<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Non-Small Cell Lung Cancer market has undergone a transformative shift over the past decade, driven by several key factors. The rise in the number of NSCLC cases, combined with the increasing adoption of approved therapies, especially immune checkpoint inhibitors, has significantly contributed to market expansion. <\/p>\n\n\n\n<p>Furthermore, the growing awareness of genetic mutations such as <strong>KRAS, BRAF, and c-Met, <\/strong>along with advancements in mutation analysis, has played a pivotal role in guiding treatment decisions and facilitating the development of molecularly targeted therapies.<\/p>\n\n\n\n<p>The market is also expected to benefit from the anticipated entry of emerging, premium-priced therapies. For EGFR-positive NSCLC, third-generation <strong>EGFR inhibitors,<\/strong> such as <strong>AstraZeneca\u2019s TAGRISSO,<\/strong> are projected to dominate. Other promising therapies include<strong> AbbVie\u2019s Telisotuzumab Vedotin <\/strong>and the joint <strong>collaboration <\/strong>between <strong>AstraZeneca and Daiichi Sankyo, <\/strong>which has led to the development of Datopotamab Deruxtecan\u2014both of which have the potential to create a substantial impact on the market.<\/p>\n\n\n\n<p>By the end of 2024, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" class=\"ek-link\">Non-small cell lung cancer<\/a> market size in the United States is projected to reach approximately <strong>USD 12,600 million<\/strong>, with key therapeutic areas, including <strong>PD-L1, EGFR, ALK, and KRAS, <\/strong>contributing significantly to market growth. These advances, along with the launch of new therapies, are expected to drive continued growth in the NSCLC market throughout the forecast period of 2020-2034.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-1024x194.jpg\" alt=\"Non-Small Cell Lung Cancer Market Outlook\" class=\"wp-image-30473\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-1024x194.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-300x57.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-150x28.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-768x145.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-1536x291.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>According to the World Health Organization (WHO), in 2022, there were approximately 2.5 million new cases of lung cancer globally, which accounted for 12.4% of all newly diagnosed cancer cases. Lung cancer continues to be one of the most common and deadly malignancies worldwide, with significant contributions to global cancer morbidity and mortality rates. The [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[6733,12555,6732,6734,1111],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-6303","post","type-post","status-publish","format-standard","hentry","category-articles","category-facts-and-figures","tag-non-small-cell-lung-cancer","tag-non-small-cell-lung-cancer-market","tag-non-small-cell-lung-cancer-pipeline","tag-non-small-cell-lung-cancer-pipeline-market","tag-nsclc","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Non-Small Cell Lung Cancer Market<\/title>\n<meta name=\"description\" content=\"Non-Small Cell Lung Cancer Market size is expected to escalate owing to upcoming NSCLC therapies, increasing NSCLC prevalence, and increased awareness.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Non-Small Cell Lung Cancer Market\" \/>\n<meta property=\"og:description\" content=\"Non-Small Cell Lung Cancer Market size is expected to escalate owing to upcoming NSCLC therapies, increasing NSCLC prevalence, and increased awareness.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-29T11:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-02T12:58:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Non-Small Cell Lung Cancer Market","description":"Non-Small Cell Lung Cancer Market size is expected to escalate owing to upcoming NSCLC therapies, increasing NSCLC prevalence, and increased awareness.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market","og_locale":"en_US","og_type":"article","og_title":"Non-Small Cell Lung Cancer Market","og_description":"Non-Small Cell Lung Cancer Market size is expected to escalate owing to upcoming NSCLC therapies, increasing NSCLC prevalence, and increased awareness.","og_url":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-29T11:33:00+00:00","article_modified_time":"2024-12-02T12:58:24+00:00","og_image":[{"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png","type":"","width":"","height":""}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market","url":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market","name":"Non-Small Cell Lung Cancer Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png","datePublished":"2024-11-29T11:33:00+00:00","dateModified":"2024-12-02T12:58:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Non-Small Cell Lung Cancer Market size is expected to escalate owing to upcoming NSCLC therapies, increasing NSCLC prevalence, and increased awareness.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights.png","width":3334,"height":1826,"caption":"Non-Small Cell Lung Cancer Market Key Insights"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline Market<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 29, 2024","modified":"Updated on Dec 2, 2024"},"absolute_dates_time":{"created":"Posted on Nov 29, 2024 5:03 pm","modified":"Updated on Dec 2, 2024 6:28 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6303"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6303\/revisions"}],"predecessor-version":[{"id":30517,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6303\/revisions\/30517"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6303"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6303"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}